The Ritedose Corporation Begins Production of Drug to Alleviate National Medication Shortage
COLUMBIA, S.C. (April 25, 2023) – The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.
Ritedose Pharmaceuticals Launches New Product: <em>Arformoterol Tartrate Inhalation Solution (15 mcg/2 ml)</em>
COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a
Ritedose Awarded 503B Compounded Medications Agreement with Premier, Inc.
COLUMBIA, S.C. (January 30, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company operating one of the nation’s largest group purchasing organizations (GPOs). Effective January 1, 2023, the new agreement allows Premier members,
Ritedose Launches Two New Single-Dose Syringe Products Amid National Drug Shortage: <em>Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL)</em>
COLUMBIA, S.C. (November 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched two new unit dose syringe products, Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL). They are ready-to-use drug shortage solutions for hospital pharmacies across the country. Ritedose is a division
Ritedose Launches Critical Single-Dose Syringe Product Amid National Drug Shortage: <em>Lidocaine Hydrochloride 1% 100 mg/10 mL</em>
COLUMBIA, S.C. (October 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Lidocaine Hydrochloride 1% 100 mg/10 mL. It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation,
Ritedose Launches New 503B, Single-Dose Syringe Medications for Hospitals: <em>Rocuronium Bromide Injection (50 mg/5mL) and Rocuronium Bromide Injection (100 mg/10mL)</em>
COLUMBIA, S.C. (February 14, 2022) – Ritedose, a 25-year industry veteran in pharmaceutical development and cGMP manufacturing, just launched two new 503B critical care, unit dose syringe products – Rocuronium Bromide Injection 50 mg/5mL and Rocuronium Bromide Injection 100 mg/10mL. Ritedose 503B Outsourcing Facility is a division of Ritedose.
Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml
COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a
Ritedose Pharmaceuticals Launches Budesonide Inhalation Suspension (0.5 mg/2 ml)
COLUMBIA, S.C. (December 29, 2021) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product for hospitals, Budesonide Inhalation Suspension (0.5 mg/2 ml). It is the first of five new inhalation products scheduled for release by March 2022. Ritedose Pharmaceuticals is a
Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)</em>
COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is
Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)</em>
COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a
Recent Comments